血清IL-6浓度与NK/T细胞淋巴瘤患者临床特征及预后的关系

目的 探讨NK/T细胞淋巴瘤(NKTCL)病例血清白细胞介素6(IL-6)浓度及其与临床特征、预后的关系.方法 收集中山大学肿瘤防治中心2005年1月至2011年12月有治疗前血清的初治NKTCL病例59例,采用夹心酶联免疫吸附法检测血清IL-6水平.结果 NKTCL病例血清IL-6显著增高,49例未合并嗜血细胞综合征(Non-HLH)患者为2.56(0～22.29)pg/ml;而10例合并HLH患者为102.11(23.44～5871.24) pg/ml.在发热、晚期、高KPI评分、化疗耐药、高C反应蛋白的NK/TCL病例中,血清IL-6浓度增高患者的比例也显著增高.在生存方面,血清IL-6浓度≥3.12 pg/ml的NKTCL病例,其5年无疾病生存(PFS)率为(7.3±5.0)％,5年生存(0S)率为(17.0±7.4)％;而血清IL-6浓度＜3.12 pg/ml的NKTCL病例,其5年PFS率为(58.6±9.1)％(P=0.000),5年OS为(62.1±9.0)％(P=0.001).结论 血清IL-6水平增高与NKTCL病例高危临床特征和长期生存差相关.

The relationship between serum IL-6 level and clinical features and prognosis in patients with natural killer/T cell lymphoma

Objective To investigate the level of serum interleukine-6 (IL-6) in patients with natural killer/T-cell lymphoma (NKTCL) and its significance in clinical characteristics and prognosis.Methods From January 2005 to December 2012,59 patients with NKTCL in Cancer Center of Sun Yat-sen University were included.Serums from all patients were collected before treatment and the concentration of IL-6 was tested by sandwich ELISA.Results The level of serum IL-6 in patients with NKTCL increased significantly.The median level of IL-6 was 2.56 (0-22.29) pg/ml in 49 patients without hemophagocytic lymphohistiocytosis (HLH),and 102.11 (23.44-5 871.24) pg/ml in 10 patients with HLH.Patients with high serum IL-6 level were associated with high incidence of fever,advanced stage,high KPI score,poor chemotherapy response,high level of serum C-reactive protein.The 5-year progression free survival (PFS) and 5-year overall survival (OS) were (58.6±9.1)％ and (62.1±9.0)％ respectively in patients with ＜3.12 mg/ml serum IL-6 level,with statistically significant differences compared with (7.3±5.0)％ and (17.0±7.4)％ in patients with ≥3.12 mg/ml serum IL-6 level (P=0.000,0.001).Conclusion High level of serum IL-6 might be associated with adverse clinical features and poor survival in patients with NKTCL.